"The Biggest Scandal Since Lobotomies" - Tavistock Whistleblower Marcus Evans
27 November 2025
With Marcus Evans
UK
Marcus Evans spent four decades inside British psychiatry and watched the gender medicine experiment unfold from within Tavistock. His account — and the twenty-year whistleblower trail that preceded the Cass Review — has direct implications for Ireland, where no independent clinical review of gender services has yet been commissioned. Evans argues that treating gender dysphoria as a fixed identity rather than a psychological process represents a fundamental collapse of clinical ethics, one that Irish practitioners working in HSE-funded gender services have never been formally asked to interrogate.
Marcus Evans is a psychoanalyst and psychiatrist with 45 years of clinical experience. He served as Associate Clinical Director of the Adult Department at the Tavistock Clinic and sat on the institution's governing board until 2019, when he resigned after six months of raising concerns with executives following an internal report by clinician Dave Bell. His wife, Sue Evans, had taken an even earlier stand: she was the first Tavistock whistleblower in 2005 — two decades before the Cass Review confirmed what she had been reporting all along. The core clinical argument Evans makes concerns what he calls an overvalued belief — the conviction, held by patients and absorbed by clinicians, that a person can be born in the wrong body and that medical transition corrects this. He draws a comparison with anorexia that is worth sitting with. A therapist treating anorexia does not agree that food is poisonous; the therapist explores why the patient experiences it that way. Evans argues that affirming gender distress as identity — without exploring the psychological processes underneath — is a form of collusion that abandons the patient to their symptoms rather than helping them understand the origins of their distress. Evans traces a whistleblower timeline that should give pause to any country that has not yet conducted an equivalent of the Cass Review. A 2006 internal report apparently predicted the findings Cass reached in 2024 — and was buried. Dave Bell raised concerns formally in 2018. Marcus Evans resigned from the board in 2019. The gap between the first warning and any substantive institutional response stretched nearly twenty years. Ireland, where HSE gender services have continued to operate without an equivalent independent review, sits somewhere on a comparable timeline — without yet knowing at which point it finds itself. On the UK's new puberty-blocker trial, Evans is blunt. Two years of follow-up is insufficient to evaluate the consequences of intervening in adolescent development. What is needed, he argues, is observation in midlife — when patients are in their thirties and forties, when questions of fertility, surgical outcomes and psychological settlement can be meaningfully assessed. Designing a trial with a short endpoint does not answer the questions that actually matter. Evans's overarching frame is developmental. Young people struggling with identity are, in his view, particularly susceptible to ideological systems that offer certainty and belonging. The therapeutic obligation is to help a young person tolerate ambiguity and continue developing — not to foreclose that development with irreversible medical decisions. No Irish authority has commissioned the kind of independent review that produced the Cass Report in England, and Evans's account of what twenty years of institutional silence produced at Tavistock makes that absence difficult to overlook.
